Annual Accounts Payable
$1.67 M
+$724.00 K+76.45%
31 December 2023
Summary:
Akari Therapeutics annual accounts payable is currently $1.67 million, with the most recent change of +$724.00 thousand (+76.45%) on 31 December 2023. During the last 3 years, it has fallen by -$1.71 million (-50.57%). AKTX annual accounts payable is now -61.32% below its all-time high of $4.32 million, reached on 31 December 2015.AKTX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$4.78 M
+$96.00 K+2.05%
01 September 2024
Summary:
Akari Therapeutics quarterly accounts payable is currently $4.78 million, with the most recent change of +$96.00 thousand (+2.05%) on 01 September 2024. AKTX quarterly accounts payable is now at all-time high.AKTX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKTX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +76.5% | - |
| 3 y3 years | -50.6% | +148.6% |
| 5 y5 years | +5.3% | +263.5% |
AKTX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -50.6% | +76.5% | at high | +364.0% |
| 5 y | 5 years | -50.6% | +76.5% | at high | +395.0% |
| alltime | all time | -61.3% | +200.8% | at high | +1515.5% |
Akari Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.78 M(+2.0%) |
| June 2024 | - | $4.69 M(+46.1%) |
| Mar 2024 | - | $3.21 M(+92.0%) |
| Dec 2023 | $1.67 M(+76.5%) | $1.67 M(+62.1%) |
| June 2023 | - | $1.03 M(-37.0%) |
| Dec 2022 | $947.00 K(-47.1%) | - |
| June 2022 | - | $1.63 M(-46.9%) |
| Mar 2022 | - | $3.08 M(+72.0%) |
| Dec 2021 | $1.79 M(-47.1%) | $1.79 M(-7.0%) |
| Sept 2021 | - | $1.92 M(+14.1%) |
| June 2021 | - | $1.69 M(-40.5%) |
| Mar 2021 | - | $2.83 M(-16.2%) |
| Dec 2020 | $3.38 M(+175.1%) | $3.38 M(+40.3%) |
| Sept 2020 | - | $2.41 M(+10.0%) |
| June 2020 | - | $2.19 M(+126.8%) |
| Mar 2020 | - | $966.10 K(-21.4%) |
| Dec 2019 | $1.23 M(-22.5%) | $1.23 M(-6.6%) |
| Sept 2019 | - | $1.32 M(-11.2%) |
| June 2019 | - | $1.48 M(-16.0%) |
| Mar 2019 | - | $1.76 M(+11.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $1.59 M(-19.5%) | $1.59 M(+12.9%) |
| Sept 2018 | - | $1.40 M(-29.8%) |
| June 2018 | - | $2.00 M(-16.0%) |
| Mar 2018 | - | $2.38 M(+21.0%) |
| Dec 2017 | $1.97 M(-11.0%) | $1.97 M(+1.5%) |
| Sept 2017 | - | $1.94 M(-31.6%) |
| June 2017 | - | $2.84 M(+207.5%) |
| Mar 2017 | - | $924.50 K(-58.2%) |
| Dec 2016 | $2.21 M(-48.8%) | $2.21 M(+69.3%) |
| Sept 2016 | - | $1.31 M(-31.8%) |
| June 2016 | - | $1.92 M(+206.7%) |
| Mar 2016 | - | $625.40 K(-85.5%) |
| Dec 2015 | $4.32 M(+677.8%) | $4.32 M(+15.1%) |
| Sept 2015 | - | $3.75 M(+496.7%) |
| June 2015 | - | $629.00 K(+112.5%) |
| Mar 2015 | - | $296.00 K(-46.7%) |
| Dec 2014 | $555.50 K(-32.9%) | $555.50 K |
| Dec 2013 | $828.00 K(-51.2%) | - |
| Dec 2012 | $1.70 M(+23.1%) | - |
| Dec 2011 | $1.38 M | - |
FAQ
- What is Akari Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Akari Therapeutics?
- What is Akari Therapeutics annual accounts payable year-on-year change?
- What is Akari Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Akari Therapeutics?
What is Akari Therapeutics annual accounts payable?
The current annual accounts payable of AKTX is $1.67 M
What is the all time high annual accounts payable for Akari Therapeutics?
Akari Therapeutics all-time high annual accounts payable is $4.32 M
What is Akari Therapeutics annual accounts payable year-on-year change?
Over the past year, AKTX annual accounts payable has changed by +$724.00 K (+76.45%)
What is Akari Therapeutics quarterly accounts payable?
The current quarterly accounts payable of AKTX is $4.78 M
What is the all time high quarterly accounts payable for Akari Therapeutics?
Akari Therapeutics all-time high quarterly accounts payable is $4.78 M